US EditionBreakthrough Prostate Cancer Treatment Preserves Sexual Function in 84% of Patients, New Study Reveals
Summary by stocktitan.net
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
PRESERVE IRE trial demonstrates safety and efficacy in intermediate-risk prostate cancer - Interventional News
AngioDynamics has today announced the publication of results from the PRESERVE study, which assessed the safety and effectiveness of irreversible electroporation (IRE) with the NanoKnife system to ablate prostate tissue in patients with intermediate-risk prostate cancer in the journal European Urology. The NanoKnife system is a leading non-thermal, radiation-free, ablation technology designed to treat prostate tissue by using IRE technology, off…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
